A perfect example of where beautiful dosimetric arguments do not pan out for patient benefit. Hence, we run trials.
And maybe we should reconsider dosimetry. Iโm sure it matters! But we may be focusing on the wrong metrics. @NehaVapiwala@CZamboglou@alison_tree
Now we have PARTIQoL and COMPPAREโฆ.message is quite clear as to if there is any benefit of protons for localized prostate cancer.
@DrSpratticus@seanmmcbride@TylerSbrt
Kicking off the GU Rapid Oral Session at #ASCO26, #NancyMendenhall presents early results from COMPPARE, showing comparable bowel outcomes, grade โฅ2 GI toxicity (5.2% vs 5.6%), and 3-year FFBP (98.0% vs 97.9%) in LPC. #ASCO26#ProstateCancer@ASCO@OncoAlert
Ieri, presso la Camera dei Deputati, durante la II edizione degli Stati Generali della Radioterapia Oncologica promossa da #AIRO, il confronto si รจ concentrato su formazione, innovazione e futuro!
Come #AIROGiovani, abbiamo partecipato attivamente! #RadOncs4Life
Stati Generali della Radioterapia Oncologica, dalla Camera dei Deputati il confronto sul futuro delle cure contro il cancro @airo_young
๐ takethedate.it/approfondimenโฆ
This is @ESTRO_org here in Stockholm: a Swiss ๐จ๐ญ, two Italians ๐ฎ๐น, a Canadian ๐จ๐ฆ (able also to speak ๐ฃ๏ธ Italian better than my English!).
Several amazing combos of Radoncs every time!! #ESTRO26
Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging).
Twittorial below
Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)...
1/n
๐ฃ #ESTRO26 - @UmbertoRicardo e2irradiate @EORTC prospective OLIGOCARE registry of SABR for oligomets. ~2500 patients, ~3500 mets.
โก๏ธ local failure 5% at 1 year and 11% at 3 years
โก๏ธ Colorectal cancer has higher risk of progression
โก๏ธ minimum PTV dose correlated with outcome
We should aim to deliver high quality SABR to optimise control! #radonc
๐ฌ PEACE 2 phase III: Adding pelvic RT to prostate RT 3y ADT in very high-risk localized prostate cancer did NOT improve bPFS, MFS, CSS or OS. Borderline cPFS signal (HR 0.81, p=0.09). No added AEs. @PBlanchard_MD #ESTRO2026. @VedangMurthy what now?
@ESTRO_RT soon in #stockholm
itโs time for #ESTRO2026 ๐ธ๐ช
Lucky to have free wifi on board ๐ and on my way to join the unique @airo_young team!!! ๐ฎ๐น
๐ฌ AIRO Lung Academy ๐ซ
๐ 12 moduli FAD (2026โ2027) 1 modulo RES in presenza
๐จโโ๏ธ Riservata a radio-oncologi soci AIRO
๐ Numero chiuso (15 posti) โ partecipazione gratuita
๐ Iscrizioni aperte fino al 21/03/2026
๐ lnkd.in/d3waaNeC